INT44724

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 2.54
Pain Relevance 1.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
tail 1
tk (Mus musculus)
Pain Link Frequency Relevance Heat
tail-flick 6 100.00 Very High Very High Very High
midbrain 4 99.74 Very High Very High Very High
Pain 1 99.58 Very High Very High Very High
positron emission tomography 48 98.60 Very High Very High Very High
Rostral ventromedial medulla 3 93.16 High High
imagery 42 92.32 High High
Antinociceptive 1 70.84 Quite High
palliative 1 57.04 Quite High
Central nervous system 10 5.00 Very Low Very Low Very Low
anesthesia 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloid Leukemia 128 98.76 Very High Very High Very High
Metastasis 6 97.54 Very High Very High Very High
Cancer 121 96.64 Very High Very High Very High
Leukemia 12 95.60 Very High Very High Very High
Non-small-cell Lung Cancer 30 71.28 Quite High
Disease 13 64.40 Quite High
Recurrence 5 50.04 Quite High
Lung Cancer 15 50.00 Quite Low
Solid Tumor 1 23.92 Low Low
Glioblastoma 14 17.28 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Imatinib mesylate, a BCR-ABL TK inhibitor, is the frontline therapy for CML.
Negative_regulation (inhibitor) of TK associated with myeloid leukemia
1) Confidence 0.26 Published 2009 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2697539 Disease Relevance 0.45 Pain Relevance 0
Various clinical trial results provided evidence that resistance to one TK inhibitor can be reversed with the use of a different TK inhibitor (TKI).
Negative_regulation (inhibitor) of TK
2) Confidence 0.22 Published 2009 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2697539 Disease Relevance 0.63 Pain Relevance 0
Although most of these TK inhibitor tracers showed promising and potential characteristics in vitro, none of them proved successful in the clinical setting.
Negative_regulation (inhibitor) of TK
3) Confidence 0.11 Published 2010 Journal Mol Imaging Biol Section Body Doc Link PMC2978890 Disease Relevance 0.48 Pain Relevance 0.27
New PET probes, including labeled monoclonal Abs and small molecules such as TK inhibitors, have been developed and evaluated in the preclinical setting for EGFR visualization [8–25].
Negative_regulation (inhibitors) of TK associated with positron emission tomography
4) Confidence 0.11 Published 2010 Journal Mol Imaging Biol Section Body Doc Link PMC2978890 Disease Relevance 0.55 Pain Relevance 0.27
The autophosphorylation triggered by the TK promotes multiple intracellular signaling pathways, ultimately causing cancer cell proliferation, invasion, and metastases.6 The EGFR pathway may be inhibited by a monoclonal antibody that prevents the ligand binding or by a small molecule that inhibits the TK activity.
Negative_regulation (inhibits) of TK associated with cancer and metastasis
5) Confidence 0.02 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2880342 Disease Relevance 0.44 Pain Relevance 0.06
Midbrain stimulation inhibits tail-flick only at currents sufficient to excite rostral medullary neurons.
Negative_regulation (inhibits) of tail-flick in tail associated with tail-flick and midbrain
6) Confidence 0.01 Published 1984 Journal Brain Res. Section Title Doc Link 6498508 Disease Relevance 0 Pain Relevance 0.71

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox